Cochrane · systematic review · CD007313
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children
Cates, CJ, Karner, C · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 30%Moderate 5 · 50%High 2 · 20%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
160/4.5 mcg BDF single inhaler therapy compared to current best practice for adult asthma that is not controlled on ICS
Population: adults with asthma that is not controlled on ICS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Patients with exacerbations causing hospitalisation 160/4.5 mcg BDF single inhaler therapy vs current best practice | OR 0.81 [0.45, 1.44] | 8 studies · 8841 participants | Low |
Patients with exacerbations treated with oral steroids 160/4.5 mcg BDF single inhaler therapy vs current best practice | OR 0.83 [0.7, 0.98] | 8 studies · 8841 participants | Moderate |
Fatal serious adverse events 160/4.5 mcg BDF single inhaler therapy vs current best practice | OR 1.95 [0.53, 7.21] | 8 studies · 8841 participants | Low |
Serious adverse events (non‐fatal) 160/4.5 mcg BDF single inhaler therapy vs current best practice | OR 1.2 [0.9, 1.6] | 8 studies · 8841 participants | Low |
Discontinuation due to adverse events 160/4.5 mcg BDF single inhaler therapy vs current best practice | OR 2.85 [1.89, 4.3] | 7 studies · 8411 participants | Moderate |
Single inhaler therapy compared to fixed dose ICS for asthma in adults not controlled on regular ICS
Population: patients with asthma in adults not controlled on regular ICS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Patients with exacerbations causing hospitalisation Single inhaler therapy vs fixed dose ICS | OR 0.56 [0.28, 1.09] | 3 studies · 4209 participants | Moderate |
Patients with exacerbations treated with oral steroids Single inhaler therapy vs fixed dose ICS | OR 0.54 [0.45, 0.64] | 4 studies · 4280 participants | High |
Fatal serious adverse events Single inhaler therapy vs fixed dose ICS | OR 0.37 [0.05, 2.62] | 3 studies · 4209 participants | Moderate |
Serious adverse events (non‐fatal) Single inhaler therapy vs fixed dose ICS | OR 0.97 [0.73, 1.29] | 3 studies · 4209 participants | Moderate |
Discontinuation due to adverse events Single inhaler therapy vs fixed dose ICS | OR 0.57 [0.35, 0.93] | 2 studies · 2586 participants | High |